Compare TG Therapeutics Inc (TGTX) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Teucrium Wheat Fund — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while Teucrium Wheat Fund trades at $24.41 (market cap $273.67M). The key difference: TG Therapeutics Inc is far larger — about 29.8× Teucrium Wheat Fund's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Teucrium Wheat Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Teucrium Wheat Fund for 40 Days on average.
| TGTX | WEAT | |
|---|---|---|
Market Cap | $8.16B | $273.67M |
Volume | 1,735,121 | 222,576 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $59.06 | $28.00 |
52-Week Low | $26.94 | $19.88 |
Typical Hold Time | 16 Days | 40 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
WEAT is trading at $24.41, down 1.97% with a bearish technical outlook as moving averages signal selling pressure. The wheat ETF faces mixed sentiment with recent price gains of 9.9% over the past month but current technical indicators showing weakness. Key support sits at $24 with resistance at $25, creating a tight trading range.
The ETF's performance remains tied to agricultural commodity volatility and inflation trends. Recent inflation data shows prices above Fed targets, potentially supporting commodity investments. However, technical weakness and the question of whether the recent rally is overdone present near-term challenges for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
